https://www.selleckchem.com/pr....oducts/daratumumab.h
3±268. mL vs. (714.1±618.5) mL, p=0.001], and shorter chest tube duration [(3.6±1.7) days vs. (4.2±2.6) days, p=0.014]; however, a similar incidence of chylothorax [3 (2.6%) vs. 7 (6.4%), p=0.207] was recorded. Multivariate logistic regression analysis indicated that neoadjuvant therapy was an independent positive factor of chylothorax (odd ratio [OR] = 9.257; 95% confidence interval [CI] 1.434-59.773, p=0.019); whereas high-volume experience of the surgeon was an independent negative factor of this complication (OR = 0.129; 95% CI
Like
Comment
Share
